menu
    • menu

    Company profile for Femasys

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    FemasysUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3950 Johns Creek Court, Suite 100 Suwanee, GA 30024
    Telephone
    Telephone
    877-336-2562
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://femasys.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Femasys Launches Femaseed Complete For OB/GYNs At ACOG 2026
    Femasys Launches Femaseed Complete For OB/GYNs At ACOG 2026

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3279022/0/en/femasys-launches-femaseed-complete-for-ob-gyns-at-acog-2026.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share
    Femasys Appoints John Canning COO to Drive Execution & Growth
    Femasys Appoints John Canning COO to Drive Execution & Growth

    01 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/01/3266688/0/en/Femasys-Appoints-John-Canning-as-Chief-Operating-Officer-to-Drive-Operational-Execution-and-Advance-Commercial-Growth.html

    GLOBENEWSWIRE
    01 Apr 2026
    Share Share
    Femasys Reveals 2025 Financial Results And Corporate Update
    Femasys Reveals 2025 Financial Results And Corporate Update

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3266020/0/en/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2025-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors
    Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258217/0/en/Femasys-Appoints-Dr-Kenneth-D-Eichenbaum-to-Board-of-Directors.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Femasys Progresses Fembloc For U.S. Approval With Pivotal Trial
    Femasys Progresses Fembloc For U.S. Approval With Pivotal Trial

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3252904/0/en/Femasys-Advances-FemBloc-Toward-U-S-Approval-with-Initiation-of-Pivotal-Trial-Enrollment.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    Femasys Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
    Femasys Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246836/0/en/Femasys-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search